Director/PDMR Shareholding
15 November 2024 10:00 GMT
Transaction by Person Discharging Managerial Responsibilities
AstraZeneca PLC (the Company) announces that it was notified on 14 November 2024 that Pascal Soriot, Chief Executive Officer, purchased 20,000 of the Company's ordinary shares of $0.25 each (Ordinary Shares) on 14 November 2024, as set out below.
| PDMR | Position | Nature of the transaction | Quantity | Price |
| Pascal Soriot | Chief Executive Officer | Purchase of Ordinary Shares | 20,000 | GB£102.03 |
Further details are set out in the attached notification, made in accordance with the requirements of the EU Market Abuse Regulation (since it forms part of UK law pursuant to the European Union (Withdrawal) Act 2018).
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |||||
| a) | Name | Pascal Soriot | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Chief Executive Officer | ||||
| b) | Initial notification /Amendment | Initial notification | ||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) | Name | AstraZeneca PLC | ||||
| b) | LEI | PY6ZZQWO2IZFZC3IOL08 | ||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) | Description of the financial instrument, type of instrumentIdentification code | Ordinary Shares of US$0.25 each in AstraZeneca PLCGB0009895292 | ||||
| b) | Nature of the transaction | Purchase of AstraZeneca PLC Ordinary Shares of US$0.25 | ||||
| c) | Price(s) and volume(s) |
|
||||
| d) | Aggregated information- Aggregated volume- Price | Not applicable - single transaction | ||||
| e) | Date of the transaction | 14 November 2024 | ||||
| f) | Place of the transaction | LON | ||||
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZeneca
Contacts
For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.
Adrian Kemp
Company Secretary
AstraZeneca PLC
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.